4332 Stock Chart & Stats
HK$0.18
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.18
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$1,761.00
Previous CloseN/A
Volume50.00
Average Volume (3M)0.00
Market Cap
HK$1.63T
Enterprise ValueHK$240.31K
Total Cash (Recent Filing)HK$13.99B
Total Debt (Recent Filing)HK$57.30B
Price to Earnings (P/E)26.6
Beta-0.34
Next Earnings
Nov 03, 2026EPS Estimate
45.59Next Dividend Ex-DateN/A
Dividend Yield39524.74%
Share Statistics
EPS (TTM)16.22
Shares Outstanding539,708,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2,995.57Price Target Upside1664104.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)179.55
Revenue Forecast (FY)HK$303.12B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistently strong free cash flow (TTM ~$10.2B and robust Q2 generation) provides durable internal funding for R&D, capex, dividends and targeted buybacks. This cash conversion supports strategic flexibility to invest in pipeline and manufacturing without excessive dilution.
Diversified High-Growth Product BaseA broad portfolio with many >$1B products and multiple high-growth drivers reduces reliance on any single franchise. Diversification across oncology, CV, inflammation, rare disease and biosimilars helps sustain revenue and mitigates single-product shocks as the company executes launches and penetrates new indications.
Manufacturing Scale And Late-Stage PipelineProgressing multiple late-stage programs while scaling biologics manufacturing (capex to support MariTide) strengthens Amgen's ability to commercialize new biologics at scale. In-house capacity plus pipeline readouts are structural advantages for long-term market share and margin maintenance.
Bears Say
High LeverageMaterial leverage constrains financial flexibility and increases sensitivity to rising rates or earnings volatility. With operating cash flow covering less than half of total debt, sizable interest and refinancing considerations could limit pace of buybacks, M&A or cushion for adverse outcomes over the medium term.
Legacy Brand Erosion From BiosimilarsSignificant decline in legacy osteoporosis franchises due to biosimilar entry reflects sustainable, structural revenue loss as exclusivity lapses. Replacing that cash flow requires successful commercialization of new assets and price/access wins in competitive markets, which takes time and capital.
Rising Cost Base And Near-Term Expense IncreasesHigher profit-sharing, royalty expenses and planned increases in R&D and BD-related spend exert structural pressure on gross and operating margins. Sustained higher costs will reduce incremental cash available for deleveraging or returns until productivity gains or pricing/mix improvements materialize.
Amgen News
4332 FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was HK$0.18 and its highest was HK$1761.00 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is HK$1.63T.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Nov 03, 2026 which is in 86 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 04, 2026. The company reported HK$49.343 earnings per share for the quarter, beating the consensus estimate of HK$44.064 by HK$5.28.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of HK$19.772 which represents an annual dividend yield of 39524.74%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 45.59.
How many shares outstanding does Amgen have?
Amgen has 539,708,250 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of HK$49.343 in its last earnings report, beating expectations of HK$44.064. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in HK:4332
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$2,995.57 (1664104.91% Upside)
HK$2,995.57 (1664104.91% Upside)
Blogger Sentiment
Bullish
HK:4332 Sentiment 88%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 97%
Bearish news 3%
Bearish news 3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.53%
12-Months-Change
Fundamentals
Return on Equity
39524.74%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
4332 Company Deck
4332 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based commercial strength (10% revenue growth, multiple products with double-digit increases, raised full-year guidance), robust margins (48% non-GAAP operating margin) and strong cash generation, while also flagging expected near-term expense increases, higher cost-of-sales pressure from mix and profit-share, a material decline in the Prolia/XGEVA franchise (–33%), and some pipeline uncertainty/readouts pending. On balance the positive commercial execution, raised guidance and pipeline momentum outweigh the noted headwinds.View all HK:4332 earnings summaries4332 Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
4332 Stock 12 Month Forecast
Average Price Target
HK$2,995.57
―